Sun Pharma inks pact with AstraZeneca

Sun Pharmaceutical Industries has entered into an agreement with AstraZeneca Pharma India to distribute the latter's Axcer brand, used for treatment of acute coronary syndrome.

AstraZeneca Pharma India already has a trademarked brand (Brilinta) for the molecule in question, ticagrelor, launched and marketed by AstraZeneca Pharma India since 2012.

"This collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of acute coronary syndrome patients. It strengthens Sun Pharmaceutical's cardiology portfolio with the addition of a new patented therapy," went a company statement on Tuesday.

Abhay Gandhi, chief executive of Sun Pharmaceutical's India business, said: "Such collaborations are a part of our stated policy of becoming the partner of choice for promotion and distribution of innovative pharmaceutical products in the country."
 

Shares of Sun Pharma closed at Rs 860.30, down by 2.1 per cent, on Tuesday on the BSE exchange.